1. Health technology

  2. •

    Pharmaceuticals: major
GALDERMA GROUP AG

GALDERMA GROUP AG

46.30
USD
+0.79
(+1.74%)
48.48BMarket Cap
GALDERMA GROUP AG
OTC:GALDY
(OTC Markets)

Recent

price

46.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
CHF
2.65
2.98
2.92
3.4
3.52
- -
Revenue per Share
-0.12
-0.08
-0.04
0.18
0.41
- -
Basic EPS, GAAP
0.15
0.09
0.12
0.37
0.8
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.03
- -
Dividend per Share
- -
- -
3.81
5.97
5.52
5.52
Book Value per Share
- -
- -
-3.32
-1.66
-1.1
-1.1
Tangible Book Value per Share
1,185
1,185
1,185
1,184
1,179
1,179
Basic Weighted Avg Shares
3,142
3,533
3,463
4,028
4,153
- -
Sales/Revenue/Turnover
10.37
10.62
14.84
15.27
16.71
- -
Operating Margin (%)
231
257
232
266
256
- -
Depreciation Expense
-141
-91
-48
210
486
- -
Net Income, GAAP
- -
- -
618.18
25.48
4.08
- -
Effective Tax Rate (%)
-4.48
-2.58
-1.38
5.2
11.7
- -
Profit Margin (%)
- -
- -
38
286
303
303
Working Capital
- -
- -
4,076
2,471
2,131
2,131
LT Debt
- -
- -
4,516
7,067
6,457
6,457
Total Equity
- -
- -
- -
4.74
6.85
- -
Return on Invested Capital (%)
- -
- -
- -
4.94
6.8
- -
Return on Capital (%)
- -
- -
- -
3.62
7.18
- -
Return on Common Equity (%)

Capital Structure

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
33
45
52
LT Borrowings
2,392
2,138
2,044
LT Finance Leases
79
73
87
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,184
1,171
1,170
Market Capitalization
24,107
27,154
38,413

Working Capital

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1,672
1,514
1,931
Cash, Cash Equivalents & STI
415
363
618
Accounts Receivable, Net
684
679
708
Inventories
366
398
416
Total Current Liabilities
1,386
1,387
1,628
Payables & Accruals
- -
- -
- -
ST Debt
33
45
52
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-8.63%
Free Cash Flow
- -
- -
112.1%
Net Income, GAAP
- -
- -
131.79%
Sales/Revenue/Turnover
- -
- -
3.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3,463
2024
- -
- -
- -
- -
4,028
2025
- -
- -
- -
- -
4,153

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.04
2024
- -
- -
- -
- -
0.18
2025
- -
- -
- -
- -
0.41

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.03
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business